Procyrion Stock

Procyrion develops technology solutions and offers a catheter-based circulatory support technologies.

Sign up today and learn more about Procyrion Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Procyrion Stock

Procyrion develops technology solutions and offers a catheter-based circulatory support technologies. One in five adults over the age of 40 will develop heart failure in his or her lifetime. For the sickest patients, only 1% receive treatment annually due to scarcity, cost, and high risk of current solutions. Procyrion, has developed a solution: Aortix is a circulatory support pump implanted without surgery. Thinner than a #2 pencil, a cardiologist can implant Aortix through a catheter in the leg, deploying it between the heart and the kidneys to unload the failing heart and perfuse vital organs. This first-in-class device allows the heart to rest and heal while correcting the fluid imbalance. The company was founded in 2005 and is based in Houston, Texas.

Funding History

February 2013$2.9M
December 2014$650K
July 2015$5.2M
October 2015$10.0M
January 2018$16.0M
July 2019$30.0M
February 2024$47.7M
February 2024$10.0M

Management

President & CEO

Benjamin A. Hertzog

Chief Operating Officer

Jason Heuring

Founder & Chief Medical Officer

Reynolds M. Delgado III

Director, Research and Development

William Clifton MD

President and CEO

Eric Fain

Board Member

Leo Linbeck III

Investor & Board Member

Jeff Bird

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo